This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
New CDC Data Review Prompts Renewed Call for PCV13 Immunization
Family Physicians Encouraged to Make the Transition From PCV7 to PCV13
By News Staff
In December 2010, the CDC's Advisory Committee on Immunization Practices, or ACIP, recommended that health care professionals begin using a newly approved 13-valent pneumococcal conjugate vaccine, or PCV13, instead of PCV7, with doses given at ages 2, 4, 6 and 12-15 months. PCV13 is approved for use in children ages 6 weeks to 71 months.
- Approval of a 13-valent pneumococcal conjugate vaccine, or PCV13, last year means that children can be protected from 13 common serotypes of Streptococcus pneumoniae, including the serotypes that now most commonly cause invasive pneumococcal disease.
- The vaccine is recommended for use in children at ages 2, 4, 6 and 12 through 15 months.
- Children ages 14 through 59 months who have completed the full series of the previously recommended seven-valent pneumococcal vaccine should receive a single supplemental dose of PCV13.
Because patients who have received only the PCV7 vaccine remain at risk for IPD caused by serotypes unique to PCV13, the CDC is urging health care professionals to
- review patients' immunization records;
- provide patients ages 14 months through 59 months who have completed the full PCV7 series a supplemental dose of PCV13 at the next scheduled office visit if they have not yet received the new vaccine; and
- use PCV13 rather than PCV7 vaccine, even if office supplies of PCV7 are not yet exhausted.
CDC: Pneumococcal Conjugate Vaccine Information Statement (2-page PDF; About PDFs)